CN117120100A - 前列腺癌的诊断方法 - Google Patents
前列腺癌的诊断方法 Download PDFInfo
- Publication number
- CN117120100A CN117120100A CN202280026305.2A CN202280026305A CN117120100A CN 117120100 A CN117120100 A CN 117120100A CN 202280026305 A CN202280026305 A CN 202280026305A CN 117120100 A CN117120100 A CN 117120100A
- Authority
- CN
- China
- Prior art keywords
- radioligand
- psma
- imaging agent
- pet
- imaging
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/121—Solutions, i.e. homogeneous liquid formulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21305432 | 2021-04-02 | ||
| EP21305432.3 | 2021-04-02 | ||
| PCT/EP2022/058754 WO2022207906A1 (en) | 2021-04-02 | 2022-04-01 | Diagnostic methods of prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117120100A true CN117120100A (zh) | 2023-11-24 |
Family
ID=75588163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280026305.2A Pending CN117120100A (zh) | 2021-04-02 | 2022-04-01 | 前列腺癌的诊断方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240181092A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4313175A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024514293A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230165761A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117120100A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3215723A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL307381A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202304531A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022207906A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3972627A4 (en) | 2019-05-20 | 2023-06-21 | Endocyte, Inc. | Methods for preparing psma conjugates |
| WO2022106629A1 (en) | 2020-11-19 | 2022-05-27 | Novartis Ag | Synthesis of prostate specific membrane antigen (psma) ligands |
| CN120897762A (zh) * | 2023-04-12 | 2025-11-04 | 康奈尔大学 | 用于治疗癌症的放射治疗缀合物 |
| WO2026027442A1 (en) | 2024-08-01 | 2026-02-05 | Novartis Ag | Synthesis of a precursor of radiopharmaceutical products |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020528461A (ja) * | 2017-07-28 | 2020-09-24 | テクニシェ ユニバーシタット ミュンヘン | デュアルモードの放射性トレーサーおよび療法剤 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013173630A1 (en) * | 2012-05-16 | 2013-11-21 | Cancer Targeted Technology, Llc | Formulation of radiopharmaceuticals containing multiple acidic groups |
| WO2013173583A1 (en) | 2012-05-16 | 2013-11-21 | Cancer Targeted Technology, Llc | Psma inhibitors |
| SMT202300035T1 (it) * | 2013-03-15 | 2023-05-12 | Cancer Targeted Tech Llc | Metodi per preparare agenti di pet imaging marcati con 18f indirizzati al psma e metodi diagnostici con gli stessi |
-
2022
- 2022-04-01 CA CA3215723A patent/CA3215723A1/en active Pending
- 2022-04-01 WO PCT/EP2022/058754 patent/WO2022207906A1/en not_active Ceased
- 2022-04-01 KR KR1020237032903A patent/KR20230165761A/ko active Pending
- 2022-04-01 IL IL307381A patent/IL307381A/en unknown
- 2022-04-01 EP EP22720606.7A patent/EP4313175A1/en active Pending
- 2022-04-01 JP JP2023560269A patent/JP2024514293A/ja active Pending
- 2022-04-01 TW TW111112920A patent/TW202304531A/zh unknown
- 2022-04-01 CN CN202280026305.2A patent/CN117120100A/zh active Pending
- 2022-04-01 US US18/552,760 patent/US20240181092A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020528461A (ja) * | 2017-07-28 | 2020-09-24 | テクニシェ ユニバーシタット ミュンヘン | デュアルモードの放射性トレーサーおよび療法剤 |
Non-Patent Citations (2)
| Title |
|---|
| AFSHAR-OROMIEH 等: "The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer", EUR J NUCL MED MOL IMAGING, 31 December 2015 (2015-12-31), pages 197 - 209 * |
| SPENCER C. BEHR 等: "Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer", JOURNAL OF NUCLEAR MEDICINE, vol. 60, no. 7, 1 July 2019 (2019-07-01), pages 910 - 916 * |
Also Published As
| Publication number | Publication date |
|---|---|
| TW202304531A (zh) | 2023-02-01 |
| JP2024514293A (ja) | 2024-04-01 |
| WO2022207906A1 (en) | 2022-10-06 |
| IL307381A (en) | 2023-11-01 |
| KR20230165761A (ko) | 2023-12-05 |
| CA3215723A1 (en) | 2022-10-06 |
| EP4313175A1 (en) | 2024-02-07 |
| US20240181092A1 (en) | 2024-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hicks et al. | 64Cu-SARTATE PET imaging of patients with neuroendocrine tumors demonstrates high tumor uptake and retention, potentially allowing prospective dosimetry for peptide receptor radionuclide therapy | |
| Granov et al. | Positron emission tomography | |
| Rauscher et al. | Intrapatient comparison of 111In-PSMA I&T SPECT/CT and hybrid 68Ga-HBED-CC PSMA PET in patients with early recurrent prostate cancer | |
| McCarthy et al. | Comparison of PSMA-HBED and PSMA-I&T as diagnostic agents in prostate carcinoma | |
| JP2024514293A (ja) | 前立腺がんの診断方法 | |
| Natarajan et al. | Development of a novel long-lived immunoPET tracer for monitoring lymphoma therapy in a humanized transgenic mouse model | |
| La et al. | Progress of coordination and utilization of zirconium-89 for positron emission tomography (PET) studies | |
| US20250025584A1 (en) | Radiopharmaceutical treatment methods and use | |
| JP2017503763A (ja) | Gcc発現細胞を撮像するための化合物及び組成物 | |
| Ilem-Ozdemir et al. | Nuclear medicine and radiopharmaceuticals for molecular diagnosis | |
| Hodolic et al. | Safety and tolerability of 68Ga-NT-20.3, a radiopharmaceutical for targeting neurotensin receptors, in patients with pancreatic ductal adenocarcinoma: the first in-human use | |
| US20250269073A1 (en) | [177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof | |
| Vernekar et al. | Radiopharmaceuticals: a new vista for diagnosis and treatment of thyroid cancer | |
| Velikyan et al. | GMP production of [68Ga] Ga-BOT5035 for imaging of liver fibrosis in microdosing phase 0 study | |
| US20250121103A1 (en) | [177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof | |
| Suh et al. | Phase I clinical trial of prostate-specific membrane antigen-targeting 68Ga-NGUL PET/CT in healthy volunteers and patients with prostate cancer | |
| KR20260049617A (ko) | Cu-64 psma i&t 주사를 사용하여 인간 대상체에서 전립선암을 검출하는 방법 | |
| US20250032651A1 (en) | [177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof | |
| O'Brien et al. | Managing a high-specific-activity iobenguane therapy clinic: from operations to reimbursement | |
| US20260115337A1 (en) | [177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof | |
| US20240042067A1 (en) | [177lu] lutetium-psma i&t composition, kit, method of making, and method of using thereof | |
| Lucignani | Non-standard PET radionuclides: time to get ready for new clinical PET strategies | |
| Elison et al. | ANZSNM ASM 2021 POSTER PRESENTATIONS | |
| WO2026019453A1 (en) | [177lu]lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof | |
| HELIA | XVII CONGRESS OF THE HEVESY GYÖRGY HUNGARIAN SOCIETY OF NUCLEAR MEDICINE-poster session |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20240202 Address after: Basel, SUI Applicant after: NOVARTIS AG Country or region after: Switzerland Address before: French Ruez Farmar Meisong Applicant before: Advanced accelerator applications Inc. Country or region before: France Applicant before: NOVARTIS AG Country or region before: Switzerland |
|
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |